豪享彩票

+86 400-821-9890

Vision

We are devoted to providing the most comprehensive and
accurate molecular diagnostic information for every cancer
patient and for physicians to help patients get
personalized treatment.

Mission

Genomic Testing

We collaborate with hospitals and
institutes by providing
comprehensive genomic testing in
our CLIA-certificated and CAP-
accredited laboratory.

Pharmaceutical
Partnership

We partner with pharmaceutical
companies all over the world throughout
research, biomarker-driven drug
development and commercialization of
豪享彩票 new cancer therapies.

Big Data Platform

As one of the largest genomic
datasets in China, we build datasets
of Chinese cancer patients to
advance medical research and new
drug development.

Genomic Testing

We provide comprehensive tumor genomic testing to assist in personal treatment
approaches that are recognized as targeted therapies and immunotherapies.

Biomarker Discovery

Fusion-Based Biomarkers
for Targeted Therapy

We have integrated DNA and RNA sequencing results
for detection of fusion genes with higher sensitivity.

IO Biomarkers

We have leveraged multiple techniques (DNA, RNA,
IHC, etc.) to help identify immunotherapy-related
豪享彩票 biomarkers for our patients.

Laboratory

OrigiMed has 43,000 square feet of lab
space which has been built in line with
international standards and 54,000 sq.ft
of office space.

43,000 sq.ftLab Space
4PBStorage Capacity
110 TFLOPSTotal Peak Performance
2,304 CoresCPU Core Number
20.4 TB豪享彩票Total Memory

Accreditation

CAP-accredited
by The College of
豪享彩票 American Pathologists

CLIA-certificated
by The Centers for
Medicare & Medicaid
Service

NIH/CPTAC
豪享彩票 Collaboration

CSCO-OrigiMed Cancer
Genomics Data
Platform for Chinese
豪享彩票 cancer patients

CTONG-OrigiMed
New Clinical Trial
Sharing Platform

豪享彩票_安全购彩 豪享彩票_官网 豪享彩票|官方指定! 豪享彩票-豪享彩票 豪享彩票-豪享彩票